431 / 510
Cuidados
Continuos
430
Alonso A, Vilches Y, Diez L. Atención en la agonía. Psicooncologia.2008; 5:279-301
Cherny NI, Coyle N ,Foley K. Guidelines in the care of the dyng cancer patient. Hematol Oncol
Clinics of North America 1996;10:261-286
McCann RM, Hall WJ, Groth JA: Comfort care for terminally ill patients.The appropiate use of
nutrition and hydration. JAMA 1994; 272:1263-1266
Lawlor PG. Deliriumand dehydration: some fluid for thought? Support Care Cancer 2002;10: 445-454
Steiner N, Bruera E. Methods of hydration in palliative care patients. J Palliat Care 1998;14:6-13
Bruera E, Hu D, Dala S, Torres-Vigil, Trumble J, Roosth J et als. Parenteral Hydration in
Patients With Advanced Cancer: A Multicenter, Double-Blind, Placebo-Controlled Randomized
Trial. J. Clin Oncol,2013; 31 (1):111-118
Ellershaw JE, Kinder C ,Aldridge J, Allison M, Smith JC. Care of the dying : is pain control
compromised or enhaced by continuation of the fentanyl transdermal patch in the dyng phase
?. J Pain Symptom Manage 2002; 24(4):398-403
Lichter I, Hunt E. The last 48 hours of life. Journal of palliative care 1990;6(4): 7-15
Navigante AH, Monica A. Castro MA and Cerchietti LC. Morphine Versus Midazolam as
Upfront Therapy to Control Dyspnea Perception in Cancer Patients While Its Underlying Cause
Is Sought or Treated. J Pain Symptom Manage 2010;39:820-830.
Simon ST, Koskeroglu P,Gaertner J and Voltz R. Fentanyl for the Relief of Refractory
Breathlessness: A Systematic Review. J Pain Symptom Manage 2013;46:874-886.
Ben-Aharon I, Gafter-Gvili A, Paul M, Leibovici L, and. Stemmer SM. Interventions for
Alleviating Cancer-Related Dyspnea: A Systematic Review J Clin Oncol 2008;26:2396-2404.
Morita T, Tsunoda J,inoue S ,Chihara S. Risk factors for death rattle in terminally ill cancer
patients: a prospective exploratory study. Pall Med 2000; 14: 19-23
Wildiers H, Dhaenekint C, Demeulenacre P et al. Atropine, hyoscine butylbromide, or
scopolamine are equally effective for the treatment of
death rattle in terminal care. J Pain Symptom Manage 2009;38:124e133.
Breitbart W and Alici Y.Evidence-Based Treatment of Delirium in Patients With Cancer. J Clin
Oncol. 2012; 10;30(11):1206-14.
Elsayem A, Bush SH, Munsell MF, Curry E, Calderon BB, Paraskevopoulos T et als.
Subcutaneous Olanzapine for Hyperactive
or Mixed Delirium in Patients with Advanced Cancer: A Preliminary Study. J Pain Symptom
Manage. 2010 Nov;40(5):774-82
Porta J, Núñez Olarte JM, Altisent R , Gisbert A, Loncan P, Muñoz D y cols. Aspectos éticos de
la sedación en Cuidados Paliativos. Med Pal 2002; 9(1): 41-46
Morita T, Tsunoda J, Inoue S, Chiara S. A effects of high dose opioids and sedatives on survival
on terminally ill cancer patients.J Pain Symptom Manage 2001;21:282-289
Maltoni M, Scarp E, Rosati M, Derni S, Fabbr L, Martini F et al. Palliative Sedation in End-of-
Life Care and Survival:A Systematic Review. J Clin Oncol 2012;30:1378-1383
23.
24.
25.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.